Sin Wee Koh-Gale
Adult Health · Rancho Mirage, CANPI 1174989875
Payments from drug & device makers
Across 153 payments — averaging $27.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$828
- Novo Nordisk$684
- Lilly USA, LLC$439
- AbbVie$293
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$275
- Pfizer$246
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,218100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $828 |
| Novo Nordisk | 35 | $684 |
| Lilly USA, LLC | 16 | $439 |
| AbbVie | 9 | $293 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $275 |
| Pfizer | 8 | $246 |
| Kowa Pharmaceuticals America, Inc. | 4 | $153 |
| Biohaven Pharmaceuticals, Inc. | 2 | $150 |
| Boston Scientific | 1 | $147 |
| GSK | 6 | $146 |
| Dexcom, Inc. | 2 | $131 |
| AstraZeneca | 6 | $113 |
| Scilex Pharmaceuticals Inc. | 4 | $85 |
| Johnson & Johnson | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Amarin Pharma, Inc. | 3 | $55 |
| Boehringer Ingelheim | 2 | $47 |
| Exact Sciences | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Bayer | 2 | $40 |
| Merck | 2 | $33 |
| Astellas Pharma US Inc | 1 | $25 |
| GRT US Holding, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$338
- Watchman$147
- UBRELVY$125
- NURTEC ODT$124
- RYBELSUS$122
- EVENITY$122
- ZORYVE$122
- DEXCOM G7 GSS (161)$112
How this compares
$4,218 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $118,376 |
| TrulicityDulaglutide | 53 | $56,224 |
| JanuviaSitagliptin Phosphate | 53 | $50,763 |
| JardianceEmpagliflozin | 25 | $38,809 |
| TradjentaLinagliptin | 26 | $28,209 |
| Repatha SureclickEvolocumab | 32 | $24,777 |
| XareltoRivaroxaban | 18 | $23,269 |
| Serevent DiskusSalmeterol Xinafoate | 30 | $19,143 |
| MounjaroTirzepatide | 16 | $18,266 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $13,374 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,101 |
| InvokanaCanagliflozin | 11 | $11,823 |
| Praluent PenAlirocumab | 14 | $11,547 |
| Qvar RedihalerBeclomethasone Dipropionate | 35 | $9,546 |
| AlogliptinAlogliptin Benzoate | 17 | $8,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $684 | $118,37681 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $47 | $79,11969 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $439 | $74,49069 claims |
| MerckJanuvia | $33 | $50,76353 claims |
| Johnson & JohnsonXarelto, Invokana | $73 | $35,09229 claims |
| GSKBreo Ellipta, Incruse Ellipta | $146 | $20,99249 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $40 | $9,54635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Rancho Mirage
- Karolina FaysmanLos Angeles$1.1M
- Siok-Hian Tay-KelleyStanford$611K
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.